Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

News Recap TODAY

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules


Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced positive results from its second GLP-1 human pilot study (GLP-1-H24-2) on DehydraTECH-processed Rybelsus® oral capsules. Key findings include:


1. Superior tolerability: None of the 9 participants taking DehydraTECH-processed Rybelsus® capsules experienced adverse events, compared to 6 out of 9 taking standard Rybelsus® tablets.

2. Improved absorption: DehydraTECH-processed Rybelsus® capsules showed 106.9% blood concentration levels compared to standard Rybelsus® tablets.

3. Novel delivery method: A DehydraTECH-processed Rybelsus® mouth-melt format showed promising results, delivering about one-third of the drug concentration of standard tablets.

These findings suggest that Lexaria's DehydraTECH technology could potentially enhance the oral delivery and tolerability of GLP-1 drugs like semaglutide, which may lead to increased use of oral GLP-1 products in the future.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
2203 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2646Followers
    107Following
    28KVisitors
    Follow